Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the year ended December 31, 2005. For 2005, Helix BioMedix reported a net loss of $3,277,239, or $0.18 per diluted
share, compared to a net loss of $3,109,274, or $0.23 per diluted share, in the
comparable prior year period. Revenue for 2005 was $108,408 compared to $93,661
for 2004. Revenue for 2006 will be dependent on the sales of products that incorporate
the company's peptides as well as Helix BioMedix's ability to enter into collaborative
or licensing agreements with third parties.